On Thursday, Shares of eBay Inc (NASDAQ:EBAY), gain 3.55% to $27.10.
eBay Inc, and Marie Kondo, the best-selling author of “The Life Changing Magic of Tidying Up,” release an exclusive guide that makes de-cluttering an easy and enjoyable experience for parents and children. With inspiring illustrations and never-before-seen tips, the guide features downloadable “KonMari for Kids” flashcards – offering new ways for families to ready their homes and cash in on unused items, just in time for the back to school season.
eBay’s partnership with Ms. Kondo comes at a pivotal point in the year, when many parents want to earn extra money by selling items from their homes and then use that cash to cover the cost of back to school essentials. Ms. Kondo’s latest work applies her famous systematic approach to de-cluttering and distills the information into tailored, timely tips that encourage the entire family to get involved. The guide is accessible exclusively on the “People Want What You Got” section of eBay’s website at ebay.com/sellitnow, and will serve as an ongoing resource for parents.
eBay Inc. operates as a technology company that enables commerce and payments on behalf of users, merchants, retailers, and brands of various sizes in the United States and internationally.
Shares of Medtronic PLC (NYSE:MDT), inclined 1.77% to $73.52, during its last trading session.
In support of the company`s therapy innovation strategy, Medtronic plc (MDT) declared that it has signed a definitive agreement to acquire Twelve, Inc. (“Twelve”), a privately-held medical device company based in Redwood City, Calif., focused on the development of a transcatheter mitral valve replacement (TMVR) device. Twelve is the twelfth company spun out from the premier medical device incubator The Foundry.
“Upon close, this acquisition will plannedally augment our existing capabilities in the transcatheter mitral space, which represents an important growth opportunity for Medtronic,” said Sean Salmon, senior vice president and president, Coronary & Structural Heart, Medtronic. “We have followed the transcatheter mitral valve space closely and firmly believe that Twelve has the most novel technology together with a strong, proven team. The combined strengths of our organizations will significantly accelerate our ability to deliver an exciting and differentiated therapy to patients, physicians and healthcare systems around the world.”
Mitral regurgitation occurs when the heart`s mitral valve fails to close normally, allowing blood to flow backward when the heart contracts. Over time, this will lead to declining heart function and heart failure. The TMVR device under development is being designed to treat patients with mitral valve regurgitation in whom standard restorative surgery is not recommended. The majority of these patients are largely underserved with limited treatment options.
“Twelve`s technology is a truly creative solution that brings together valve technology with a unique and highly differentiated dual-stent fixation design,” said Andrew Cleeland, president and CEO, Twelve. “Our acquisition by Medtronic will create a tremendous opportunity to leverage Medtronic`s expertise and proven success in the structural heart space to advance the treatment of mitral regurgitation.”
Medtronic plc manufactures and sells device-based medical therapies worldwide. The company’s Cardiac and Vascular Group segment offers pacemakers, implantable cardioverter defibrillators, implantable cardiac resynchronization therapy devices, AF products, diagnostics and monitoring devices, and remote monitoring and patient-centered software; and heart valves, percutaneous coronary intervention stent products, surgical valve replacement and repair products, endovascular stent grafts, and peripheral vascular intervention products.
Finally, Kite Pharma Inc (NASDAQ:KITE), ended its last trade with 5.65% gain, and closed at $54.44.
Kite Pharma Inc, offered an update from the Company’s ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin’s lymphoma (NHL) who have failed preceding chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.
“We are encouraged by the progress of the KTE-C19 clinical trial and excited by the responses we have seen so far. We believe the KTE-C19 clinical findings are in line with previous results demonstrating the potential of this promising therapeutic approach,” said Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer of Kite. “In agreement with ASH, we have taken this exceptional step of providing an update on the trial in order to address recent misinformation in the market related to our clinical program. We are on track to transition to the Phase 2 portion of the trial and plan to present Phase 1 data at ASH later this year.”
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
